White Ginseng Ameliorates Depressive Behavior and Increases Hippocampal 5-HT Level in the Stressed Ovariectomized Rats

1. Introduction

Postmenopausal women experience a number of physiological and psychological changes that are closely associated with decreased circulating estrogen due to depletion of ovarian follicle [1, 2]. Since estrogen influences transmission of neurotransmitters involved in the pathophysiology of depression, menopausal women have high risk of developing depression [3]. Particularly, estrogen enhances serotonergic activity by stimulating serotonin (5-hydroxytryptamine, 5-HT) synthesis and transmission and downregulating degradation of 5-HT [4]. Serotonergic neurons from the brainstem innervate to several brain regions including the hippocampus which is well-known to play an important role in regulating cognitive functions and pathological development of mood disorders [5]. A variety of 5-HT receptors and reuptake transporters are expressed in rodent hippocampus. They are involved in maintaining homeostasis of brain function [6]. It has been shown that selective serotonin reuptake inhibitors (SSRIs) that are predominant antidepressants can ameliorate depressive symptoms of patients with major depressive disorder (MDD) by blocking reuptake of 5-HT and stimulating 5-HT receptors in the hippocampus [6]. Decreased hippocampal 5-HT level is accompanied by depressive behavior including
sleep disturbance and anhedonia in stressed rats [7, 8]. Enhancement of hippocampal 5-HT activity can reduce depressive-like behavior of stressed and ovariectomized rats [9].

Ginseng (Panax ginseng Meyer) contains over 20 ginsenosides (steroidal and nonsteroidal saponins) and non-ginsenosides as active compounds [10]. Several studies have demonstrated that ginseng possesses diverse pharmacological activities, including antidepressive, antitumor, anti-asthma, neuroprotective, and memory-improving effects [10–13]. White ginseng (Panax ginseng Meyer, WG) is a sun-dried and nonfermented ginseng. It has been revealed that ginsenoside contents of WG are Rg1,2, Rb1,3, and Rb1 [14, 15]. WG has been reported to have therapeutic effects on hyperlipidemia, obesity, cancer, and Alzheimer’s disease [14–18]. Nevertheless, antidepressant effects of WG in an animal model of menopausal depression have not been reported yet.

Thus, the objective of the present study was to examine antidepressant effect of WG in female ovariectomized rats repeatedly exposed to restraint stress. Depressive behaviors were evaluated through tail suspension test (TST) and forced swimming test (FST). Serum corticosterone (CORT) and hippocampal 5-HT levels were assessed by enzyme-linked immunosorbent assay (ELISA).

2. Materials and Methods

2.1. Subjects and Stress Procedure. Female Sprague Dawley rats aged 10 weeks (body weight: 180-200 g) were used (Samtako Animal Co., Seoul, Korea). These rats were housed under a 12 h light/dark cycle (lights on at 8 am) with controlled temperature at 22-24 ºC. They were allowed access to food and water ad libitum. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Kyung Hee University (approval number: KHUAP(SE)-13-041) and conducted in accordance with the US National Institutes of Health guidelines (Guide for the care and Use of Laboratory Animals, 8th edition, revised 2011).

Rats were randomly assigned to the following four groups: ovariectomized and restraint stressed with saline-treated group (Control), ovariectomized and restraint stressed with white ginseng (200 mg/kg, p.o.) treated group (WG200), ovariectomized and restraint stressed with white ginseng (400 mg/kg, p.o.) treated group (WG400), and ovariectomized and restraint stressed with fluoxetine (10 mg/kg, i.p.) treated group (PC). Ovariectomy was performed under general anesthesia with pentobarbital sodium (50 mg/kg, i.p.). A small dorsal midline incision was made and bilateral ovaries were dissected under aseptic condition. After incision suture, postoperative recovery was monitored daily for one week. Restraint stress was produced by forcing animals into a cone-shaped PVC to restrict forward, backward, and lateral movements for 2 hr a day for 2 weeks.

2.2. Drug Treatment. Rats were administered 200, 400 mg/kg of WG (p.o.), or 10 mg/kg of fluoxetine (i.p.) 30 min prior to stress procedure for 2 weeks. WG powder containing 5.4 mg/kg of Rg1 and Rb1 was purchased from Daedong Korea Ginseng Co. (Chungnam, Korea). It has been reported that 5 mg/kg of ginsenoside Rg1 and 8 mg/kg of Rb1 have antidepressant effect in a chronic stress-induced depressive animal model [19, 20]. In addition, it has been shown that 100 mg/kg of WG powder containing 10.44 mg/g of ginsenosides possesses neuroprotective effect in memory-deficit rat [14]. Thus, 200 and 400 mg/kg of WG (1.08 and 2.16 mg/kg of ginsenosides, respectively) were chosen in this study to examine their ameliorating effect on depressive-like behavior. Fluoxetine, an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class, was used as a positive control (PC) in this study.

2.3. Behavioral Tests

2.3.1. Tail Suspension Test. On the 14th day of drug administration, FST was performed as previously described [21] to assess antidepressant effect of WG. Briefly, rats were placed in a transparent plexiglass cylinder (20 cm in diameter x 50 cm in height) containing water at room temperature to a depth of 30 cm. Immobility time was considered when rat remained floating without movements except to keep its head above the water. It was recorded for 5 min and regarded as depressive-like behavior.

2.3.2. Forced Swimming Test. On the 14th day of the drug administration, FST was performed as previously described [21] to assess antidepressant effect of WG. Briefly, rats were placed in the transparent plexiglass cylinder (20 cm in diameter x 50 cm in height) containing water at room temperature to a depth of 30 cm. Immobility time, which considered when the rat remained floating without movements except to keep its head above the water, was recorded for 5 min and regarded as depressive-like behavior.

2.4. Measurement of Corticosterone (CORT) Level in the Serum. After behavioral tests, animals were anesthetized with sodium pentobarbital (80mg/kg, i.p.). Cardiac blood was collected and centrifuged to separate serum. Obtained samples were stored at -80 ºC until assay. Levels of CORT in serum samples were analyzed by enzyme-linked immunosorbent assay (ELISA) kit (Enzo life sciences, New York, USA) according to the manufacturer’s instructions.

2.5. Measurement of 5-HT Level in the Hippocampus. After collecting cardiac blood, brains were immediately removed and coronally sectioned using a brain matrix (ASI instruments Inc., MI, U.S.A). The hippocampus (AP: -1.92 to -3.24 mm; ML: ±0.00 to ±4.00 mm from the bregma; DV: -2.40 to -4.20 mm below the dura) was punched out on an ice-cold plate and stored at -80 ºC until assay. Obtained tissues were homogenized with protein extraction solution (iNtRON Biotechnology, Inc., Gyeonggi-do, Korea), incubated at room temperature for 30 min, and then centrifuged at 10,000xg for 15 min at 4 ºC. Supernatant was collected to a fresh tube and 5-HT concentration in duplicate aliquots was measured using an ELISA kit (Labor Diagnostika Nord,
2.6. Statistical Analysis. Statistical comparisons among different groups were analyzed using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test. Data are presented as mean ± standard error of the mean (SEM). All statistical analyses were performed using IBM SPSS Statistics 23.0 software. Statistical significance was considered when p values were less than 0.05.

3. Results

3.1. Effect of WG in the Depressive-Like Behavior. The immobility time indicating depressive-like behavior was significantly different among groups in both TST (F(3,20) = 9.714, p < 0.001, Figure 1) and FST (F(3,20) = 6.987, p < 0.01, Figure 2). Fluoxetine as a positive control (PC) significantly reduced immobility time in TST and FST compared to the control (p < 0.001 and p < 0.01, respectively). Rats administered with WG 200 and WG 400 also showed significant decrease of immobility time in TST (p < 0.05 and p < 0.01, respectively, Figure 1). In FST, WG 400-treated rats showed remarkable reduction in immobility time compared to the control (F(3,20) = 9.714, p < 0.05, Figure 2) whereas WG 200-treated group only exhibited a tendency to decrease. These results indicate that WG can alleviate depressive behavior in a dose-dependent manner.

3.2. Effect of WG in the Serum CORT Level. Serum CORT concentrations in control and drug-treated rats were analyzed. CORT levels in control, PC, WG 200, and WG 400 groups were 37.79 ± 6.75, 11.01 ± 3.60, 12.56 ± 3.09, and 14.02 ± 4.74 ng/ml, respectively (F(3.17) = 7.886, p < 0.01). As shown in Figure 3, PC, WG 200, and WG 400-administered groups exhibited significant reduction in CORT level compared to the control group (p < 0.01, p < 0.01, and p < 0.05, respectively).

3.3. Effect of WG in the Hippocampal 5-HT Level. Results of concentrations of 5-HT in the hippocampus region of the brain of control and drug-administered groups are shown in Figure 4. Hippocampal 5-HT levels in control, PC, WG 200, and WG 400 groups were 20.74 ± 2.23, 32.74 ± 3.21, 37.89 ± 3.86, and 38.54 ± 2.03 ng/mg, respectively (F(3,20) = 7.926, p < 0.01). PC- and WG-treated rats exhibited significantly higher hippocampal 5-HT concentration compared to the control (p < 0.05 and p < 0.01, respectively).

4. Discussion

Depression is an affective disorder with symptoms of psychological, neuroendocrinological, and physiological dysfunction. Many studies have been conducted to find effective antidepressive agents. The central monoaminergic system is a well-known pharmaceutical target of antidepressants. SSRIs are typically prescribed medications to treat major depressive disorder and anxiety disorder. However, they have adverse
Cort level and depressive behavior in ovariectomized rats

Estrogen. Repeated stress causes remarkable alterations in HPA-axis of postmenopausal women, a consequence of impaired regulation of HPA-axis [29–31]. Increased CORT levels in female rats are much higher than those in the control, suggesting that WG could alleviate stress-induced depressive-like behavior in a dose-dependent manner. These findings suggest that WG is a suitable alternative of SSRIs for reducing behavioral symptoms of depression.

Menopause transition increases vulnerability to stress and increases the risk of developing mood disorders [28]. Stress responses are regulated by hypothalamic-pituitary-adrenal (HPA-) axis. Sex-hormones can influence HPA-axis activity. Thus, stress responses of male and female are different. CORT levels in female rats are much higher than those in male rats after stress [29–31]. Increment of CORT level, a consequence of impaired regulation of HPA-axis and hippocampus, is associated with the development of depression [32, 33]. HPA-axis of postmenopausal women is dysregulated due to depletion of female sex hormone, estrogen. Repeated stress causes remarkable alterations in CORT level and depressive behavior in ovariectomized rats compared to nonovariectomized group [34]. Stress-induced increment in CORT level of a menopausal animal model was significantly decreased by treatment with PC and WG in the present study, indicating that WG could act on the hippocampal 5-HT system and ameliorate depressive-like behaviors which in turn might diminish CORT release.

The hippocampus is one of the important brain regions. It maintains mood balance by interacting with HPA-axis. Patients with MDD show hyperactivity of HPA-axis due to impairment of hippocampal glucocorticoid receptor-mediated negative feedback [33, 35]. Chronic stress induced-inhibition of hippocampal neurogenesis upregulates HPA-axis activity [36, 37]. 5-HT is a predominant neurotransmitter that regulates normal hippocampal neurogenesis [38]. Thus, 5-HT acts as an antidepressant by supervising stress-managing circuits in the brain. SSRIs can increase hippocampal 5-HT transmission, resulting in inhibition of depressive symptoms [39]. Our results demonstrate that WG has an antidepressant effect through enhancing 5-HT concentrations. These effects are likely to be mediated by ingredients of WG such as ginsenosides Rb1 and Rg2. For example, Rb1, one of the major active components in WG, has been reported to be able to enhance serotonergic system by increasing 5-HT synthesis, decreasing 5-HT degradation, and stimulating 5-HT2A receptor in the brain [20, 40, 41]. Activity of inhibitory 5-HT3A receptor is suppressed by treatment with Rg2 [42]. Release of dopamine and norepinephrine is also increased by administration of Rb1 in the mouse brain [20]. Rb1, a potential phytoestrogen, exhibits antidepressant effect via increasing 5-HT activity. This effect is mediated by activation of estrogen receptor [40, 43]. Thus, ginsenosides in WG might affect the hippocampal 5-HT system directly through 5-HT receptors and indirectly through estrogen receptor. In the present study, hippocampal 5-HT levels in WG-administered rats were remarkably increased compared to those in the control, suggesting that WG could alleviate stress-induced depressive behavior by stimulating the serotonergic system in the hippocampus.

5. Conclusions

In conclusion, results of this study demonstrate that white ginseng has an antidepressant efficacy in an animal model of menopausal depression. WG can enhance hippocampal 5-HT activity and suppress depressive symptom. Further studies are needed to investigate pharmacological and molecular mechanisms underlying the antidepressant effect of WG on 5-HT biosynthesis, its receptors, and interactions with other neurotransmitter systems. The present study provides evidence that WG plays an important role in activating serotonergic neurons under stressful situation. It also suggests that WG might be a reliable natural alternative of antidepressant drugs to treat menopausal depression.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.
Conflicts of Interest
The authors have no conflicts of interest to declare.

Authors’ Contributions
Daehyuk Jang and Hyun-ju Lee contributed equally to this work.

Acknowledgments
This work was supported by a grant from the National Institute of Horticultural and Herbal Science, Rural Development Administration, Republic of Korea (PJ01193201), and the 2017 research leave program grant from Kyung Hee University and Dongseo University Research Fund of 2016.

References
[1] L. Dennerstein, “Well-being, symptoms and the menopausal transition,” *Maturitas*, vol. 23, no. 2, pp. 147–157, 1996.
[2] G. D. Mishra, W. J. Brown, and A. J. Dobson, “Physical and mental health: Changes during menopause transition,” *Quality of Life Research*, vol. 12, pp. 405–412, 2003.
[3] M. Kumari, M. Stafford, and M. Marmot, “The menopausal transition was associated in a prospective study with decreased health functioning in women who report menopausal symptoms,” *Journal of Clinical Epidemiology*, vol. 58, no. 7, pp. 719–727, 2005.
[4] A. P. Borrow and N. M. Cameron, “Estrogenic mediation of serotonergic and neurotrophic systems: Implications for female mood disorders,” *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, vol. 54, pp. 13–25, 2014.
[5] D. A. N. Morrissette and S. M. Stahl, “Modulating the serotonin system in the treatment of major depressive disorder,” *CNS Spectrums*, vol. 19, supplement 1, pp. 57–68, 2014.
[6] E. Dale, A. L. Pehrson, T. Jeyarajah et al., “Effects of serotonin in the hippocampus: How SSRIs and multimodal antidepressants might regulate pyramidal cell function,” *CNS Spectrums*, vol. 21, no. 2, pp. 143–161, 2016.
[7] J. Gronli, E. Fiske, R. Murison et al., “Extracellular levels of serotonin and GABA in the hippocampus after chronic mild stress in rats. A microdialysis study in an animal model of depression,” *Behavioural Brain Research*, vol. 181, no. 1, pp. 42–51, 2007.
[8] B. Lee, B. Sur, J. Park et al., “Chronic administration of baicauein decreases depression-like behavior induced by repeated restraint stress in rats,” *Korean Journal of Physiology & Pharmacology*, vol. 17, no. 5, pp. 393–403, 2013.
[9] A. Kageyama, H. Sakakibara, W. Zhou et al., “Genistein regulated serotonergic activity in the hippocampus of ovariectomized rats under forced swimming stress,” *Bioscience, Biotechnology, and Biochemistry*, vol. 74, no. 10, pp. 2005–2010, 2010.
[10] A. S. Attele, J. A. Wu, and C.-S. Yuan, “Ginseng pharmacology: Multiple constituents and multiple actions,” *Biochemical Pharmacology*, vol. 58, no. 11, pp. 1685–1693, 1999.
[11] N. Jiang, B.-Y. Zhang, L.-M. Dong et al., “Antidepressant effects of dammarane sapogenins in chronic unpredictable mild stress-induced depressive mice,” *Phytotherapy Research*, vol. 32, no. 6, pp. 1023–1029, 2018.
[12] J. Oh, S. B. Jeon, Y. Lee et al., “Fermented red ginseng extract inhibits cancer cell proliferation and viability,” *Journal of Medicinal Food*, vol. 18, no. 4, pp. 421–428, 2015.
[13] C.-Y. Lim, J.-M. Moon, B.-Y. Kim et al., “Comparative study of Korean white ginseng and Korean Red Ginseng on efficacies of ova-induced asthma model in mice,” *Journal of Ginseng Research*, vol. 39, no. 1, pp. 38–45, 2015.
[14] S. Lee, I. Shim, G. Kim et al., “The neuroprotective effect of white ginseng (Panax ginseng CA Meyer) on the trimethyltin (TMT)-induced memory deficit rats,” *Korean Journal of Medicinal Crop Science*, vol. 19, no. 6, pp. 456–463, 2011.
[15] Y.-S. Lee, B.-Y. Cha, K. Yamaguchi et al., “Effects of Korean white ginseng extracts on obesity in high-fat diet-induced obese mice,” *Cytotechnology*, vol. 62, no. 4, pp. 367–376, 2010.
[16] L.-S. Lee, C.-W. Cho, H.-D. Hong, Y.-C. Lee, U.-K. Choi, and Y.-C. Kim, “Hypolipidemic and antioxidant properties of phenolic compound-rich extracts from white ginseng (Panax ginseng) in cholesterol-fed rabbits,” *Molecules*, vol. 18, no. 10, pp. 12548–12560, 2013.
[17] Y. Ji, Z. Rao, J. Cui et al., “Ginsenosides extracted from nanoscale Chinese white ginseng enhances anticancer effect,” *Journal of Nanoscience and Nanotechnology*, vol. 12, no. 8, pp. 6163–6167, 2012.
[18] J. G. Choi, N. Kim, E. Huh et al., “White Ginseng Protects Mouse Hippocampal Cells Against Amyloid-Beta Oligomer Toxicity,” *Phytotherapy Research*, vol. 31, no. 3, pp. 497–506, 2017.
[19] Z. Mou, Q. Huang, S.-F. Chu et al., “Antidepressive effects of ginsenoside Rgl via regulation of HPA and HPG axis,” *Biomedicine & Phamacotherapy*, vol. 92, pp. 962–971, 2017.
[20] G.-L. Wang, Z.-M. He, H.-Y. Zhu et al., “Involvement of serotoninergic, noradrenergic and dopaminergic systems in the antidepressant-like effect of ginsenoside Rbl, a major active ingredient of Panax ginseng C.A. Meyer,” *Journal of Ethnopharmacology*, vol. 204, pp. 118–124, 2017.
[21] Y. Kitada, T. Miyauchi, A. Satoh, and S. Satoh, “Effects of antidepressants in the rat forced swimming test,” *European Journal of Pharmacology*, vol. 72, no. 2-3, pp. 145–152, 1981.
[22] J. M. Ferguson, “SSRI antidepressant medications: Adverse effects and tolerability,” *Primary Care Companion to the Journal of Clinical Psychiatry*, vol. 3, no. 1, pp. 22–27, 2001.
[23] P. Brambilla, A. Cipriani, M. Hotopf, and C. Barbui, “Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data,” *Pharmacopsychiatriy*, vol. 38, no. 2, pp. 69–77, 2005.
[24] V. Castagne, P. Moser, S. Roux, and R. D. Porsolt, “Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice,” *Current Protocols in Neuroscience Chapter 8*, vol. 8, 2011, Unit 8 10A.
[25] A. V. d. Silva and J. B. Volpon, “Model of tail suspension and its effect in some mechanical properties of the rat bone,” *Acta Ortopédica Brasileira*, vol. 12, pp. 22–31, 2004.
[26] F. Borsini and A. Meli, “Is the forced swimming test a suitable antidepressant-like effect of ginsenoside Rb1, a major active ingredient of Panax ginseng C.A. Meyer,” *Neuropsychopharmacology*, vol. 29, no. 7, pp. 1321–1330, 2004.
[27] S. C. Dulawa, K. A. Holick, B. Gundersen, and R. Hen, “Effects of chronic fluoxetine in animal models of anxiety and depression,” *Neuropsychopharmacology*, vol. 29, no. 7, pp. 1321–1330, 2004.
[28] J. Vivian-Taylor and M. Hickey, “Menopause and depression: Is there a link?” *Maturitas*, vol. 79, no. 2, pp. 142–146, 2014.
[29] C. M. McCormick and I. Z. Mathews, “HPA function in adolescence: role of sex hormones in its regulation and the enduring consequences of exposure to stressors,” Pharmacology Biochemistry & Behavior, vol. 86, no. 2, pp. 220–233, 2007.

[30] I. Azogu, J. Liang, and H. Plamondon, “Sex-specific differences in corticosterone secretion, behavioral phenotypes and expression of TrkB.T1 and TrkB.FL receptor isoforms: Impact of systemic TrkB inhibition and combinatorial stress exposure in adolescence,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 86, pp. 10–23, 2018.

[31] H. F. Figueiredo, Y. M. Ulrich-Lai, D. C. Choi, and J. P. Herman, “Estrogen potentiates adrenocortical responses to stress in female rats,” American Journal of Physiology-Endocrinology and Metabolism, vol. 292, no. 4, pp. E1173–E1182, 2007.

[32] M. Ising, S. Horstmann, S. Kloiber et al., “Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - A potential biomarker?” Biological Psychiatry, vol. 62, no. 1, pp. 47–54, 2007.

[33] C. M. Pariante and S. L. Lightman, “The HPA axis in major depression: classical theories and new developments,” Trends in Neurosciences, vol. 31, no. 9, pp. 464–468, 2008.

[34] H.-J. Park, H.-S. Shim, S. Y. Chung, T. H. Lee, and I. Shim, “Soyo-san reduces depressive-like behavior and proinflammatory cytokines in ovariectomized female rats,” BMC Complementary and Alternative Medicine, vol. 14, article 34, 2014.

[35] E. R. de Kloet, E. Vreugdenhil, M. S. Oitzl, and M. Joëls, “Brain corticosteroid receptor balance in health and disease,” Endocrine Reviews, vol. 19, no. 3, pp. 269–301, 1998.

[36] R. J. Schloesser, H. K. Manji, and K. Martinowich, “Suppression of adult neurogenesis leads to an increased hypothalamo-pituitary-adrenal axis response,” NeuroReport, vol. 20, no. 6, pp. 553–557, 2009.

[37] I. Mahar, F. R. Bambico, N. Mechawar, and J. N. Nobrega, “Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects,” Neuroscience & Biobehavioral Reviews, vol. 38, pp. 173–192, 2014.

[38] M. Banasr, M. Hery, R. Printemps, and A. Daszuta, “Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone,” Neuropsychopharmacology, vol. 29, no. 3, pp. 450–460, 2004.

[39] L. Santarelli, M. Saxe, C. Gross et al., “Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants,” Science, vol. 301, no. 5634, pp. 805–809, 2003.

[40] K. Hao, P. Gong, S.-Q. Sun et al., “Beneficial estrogen-like effects of ginsenoside Rbl, an active component of Panax ginseng, on neural 5-HT disposition and behavioral tasks in ovariectomized mice,” European Journal of Pharmacology, vol. 659, no. 1, pp. 15–25, 2011.

[41] N. Yamada, H. Araki, and H. Yoshimura, “Identification of antidepressant-like ingredients in ginseng root (Panax ginseng C.A. Meyer) using a menopausal depressive-like state in female mice: Participation of 5-HT 2A receptors,” Psychopharmacology, vol. 216, no. 4, pp. 589–599, 2011.

[42] S. Choi, J.-H. Lee, S. Oh, H. Rhim, S.-M. Lee, and S.-Y. Nah, “Effects of ginsenoside Rg2 on the 5-HT3A receptor-mediated ion current in Xenopus oocytes,” Molecules and Cells, vol. 15, no. 1, pp. 108–113, 2003.

[43] D. B. Imwalle, J.-Å. Gustafsson, and E. F. Rissman, “Lack of functional estrogen receptor β influences anxiety behavior and serotonin content in female mice,” Physiology & Behavior, vol. 84, no. 1, pp. 157–163, 2005.